Our data suggest that FN1–IL17RC may play additional roles in acute lymphoblastic leukemia, bronchoalveolar carcinoma, breast cancer, cervical cancer, glioblastoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, and prostate cancer. Here, IL17RC is linked to hepatocellular carcinoma.